Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial
Ziegler D, Low PA, Litchy WJ, Boulton AJM, Vinik AI, Freeman R
Published in Diabetes Care
Key Findings
Four years of oral alpha-lipoic acid 600 mg/day did not significantly improve the primary composite endpoint, though several neuropathic impairment measures improved versus placebo.
Conclusions
Long-term alpha-lipoic acid failed its primary endpoint but slowed progression of neuropathic impairments.
Limitations
Primary endpoint negative; high dropout over 4 years; mild neuropathy population.
Supplements Studied
Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy.
Outcomes Measured
Long-term alpha-lipoic acid failed its primary composite endpoint but slowed progression of neuropathic impairments.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.